$235.29
+0.25
(+0.11%)
As of Oct 15, 2026, 12:57 AM EDT
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Aug 31, 2026, the first target we tracked for RMD.
ResMed (RMD) is trading up at $235.29 (+0.11%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on RMD
Current price targets from 3 firms average $255, median $262, ranging from $235 to $267 — the average is 8% above the current $235. Each is tracked to its date and scored the same way a member's call is.
- Stifel $219 → $235 by Oct 2027 Oct 2, 2026 via Investing.com · Stifel's track record
- RBC Capital Markets $229 → $262 by Sep 2027 Sep 15, 2026 via Investing.com · RBC Capital Markets's track record
- KeyBanc Capital Markets $240 → $267 by Aug 2027 Aug 31, 2026 via Investing.com · KeyBanc Capital Markets's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
ResMed revenue & net income history (FY2017–FY2026)
RevenueNet incomeNet margin (right axis, %)
| FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | FY2026Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.07B | $2.34B | $2.61B | $2.96B | $3.20B | $3.58B | $4.22B | $4.69B | $5.15B | $5.65B |
| Growth (year over year) | +12.4% | +13.2% | +11.4% | +13.4% | +8.1% | +11.9% | +18.0% | +10.9% | +9.8% | +9.9% |
| Gross profit | $1.20B | $1.33B | $1.49B | $1.72B | $1.84B | $2.02B | $2.36B | $2.66B | $3.05B | $3.45B |
| Gross margin | 58.1% | 57.0% | 57.3% | 58.1% | 57.5% | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% |
| Operating income | $425.8M | $541.8M | $579.3M | $809.7M | $903.7M | $1.00B | $1.13B | $1.32B | $1.69B | $1.89B |
| Operating margin | 20.6% | 23.2% | 22.2% | 27.4% | 28.3% | 28.0% | 26.8% | 28.2% | 32.7% | 33.4% |
| Net income | $342.3M | $315.6M | $404.6M | $621.7M | $474.5M | $779.4M | $897.6M | $1.02B | $1.40B | $1.52B |
| Net margin | 16.6% | 13.5% | 15.5% | 21.0% | 14.8% | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| EPS (diluted) | $2.40 | $2.19 | $2.80 | $4.27 | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
| Balance sheet | ||||||||||
| Cash and equivalents | $821.9M | $188.7M | $147.1M | $463.2M | $295.3M | $273.7M | $227.9M | $238.4M | $1.21B | $1.47B |
| Total assets | $3.47B | $3.06B | $4.11B | $4.59B | $4.73B | $5.10B | $6.75B | $6.87B | $8.17B | $8.97B |
| Total liabilities | $1.51B | $1.00B | $2.04B | $2.09B | $1.84B | $1.74B | $2.62B | $2.01B | $2.21B | $2.38B |
| Long-term debt | $1.08B | $270.0M | $1.26B | $1.16B | $643.4M | $765.3M | $1.43B | $697.3M | $658.4M | $399.4M |
| Shareholders' equity | $1.96B | $2.06B | $2.07B | $2.50B | $2.89B | $3.36B | $4.13B | $4.86B | $5.97B | $6.59B |
| Cash flow | ||||||||||
| Operating cash flow | $414.1M | $505.0M | $459.1M | $802.3M | $736.7M | $351.1M | $693.3M | $1.40B | $1.75B | $1.81B |
| Capital expenditure | $62.2M | $62.6M | $68.7M | $95.3M | $102.7M | $134.8M | $119.7M | $99.5M | $89.9M | $156.3M |
| Free cash flow | $351.8M | $442.4M | $390.3M | $706.9M | $634.0M | $216.3M | $573.6M | $1.30B | $1.66B | $1.65B |
| Dividends paid | $186.3M | $199.5M | $211.7M | $225.1M | $226.7M | $245.3M | $258.3M | $282.3M | $310.9M | $349.7M |
| Share buybacks | — | $53.8M | $22.8M | — | — | $0 | $0 | $150.0M | $300.0M | $700.0M |
RevenueNet incomeNet margin (right axis, %)
| Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 | Q4 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.22B | $1.28B | $1.29B | $1.35B | $1.34B | $1.42B | $1.43B | $1.46B |
| Growth (year over year) | +11.1% | +10.3% | +7.9% | +10.2% | +9.1% | +11.0% | +10.8% | +8.6% |
| Gross profit | $717.2M | $751.3M | $766.4M | $820.1M | $820.8M | $878.7M | $891.0M | $861.2M |
| Gross margin | 58.6% | 58.6% | 59.3% | 60.8% | 61.5% | 61.8% | 62.2% | 58.8% |
| Operating income | $387.3M | $417.2M | $426.3M | $454.5M | $446.5M | $491.7M | $499.8M | $448.7M |
| Operating margin | 31.6% | 32.5% | 33.0% | 33.7% | 33.4% | 34.6% | 34.9% | 30.7% |
| Net income | $311.4M | $344.6M | $365.0M | $379.7M | $348.5M | $392.6M | $398.7M | $383.4M |
| Net margin | 25.4% | 26.9% | 28.3% | 28.2% | 26.1% | 27.6% | 27.9% | 26.2% |
| EPS (diluted) | $2.11 | $2.34 | $2.48 | $2.58 | $2.37 | $2.68 | $2.74 | $2.64 |
| Balance sheet | ||||||||
| Cash and equivalents | $426.4M | $521.9M | $932.7M | $1.21B | $1.38B | $1.42B | $1.66B | $1.47B |
| Total assets | $7.22B | $7.14B | $7.57B | $8.17B | $8.31B | $8.50B | $8.78B | $8.97B |
| Total liabilities | $2.03B | $1.89B | $2.02B | $2.21B | $2.19B | $2.18B | $2.29B | $2.38B |
| Long-term debt | $667.6M | $662.9M | $663.1M | $658.4M | $408.7M | $403.9M | $404.2M | $399.4M |
| Shareholders' equity | $5.20B | $5.25B | $5.55B | $5.97B | $6.12B | $6.32B | $6.49B | $6.59B |
| Cash flow | ||||||||
| Operating cash flow | $325.5M | $308.6M | $578.7M | $538.8M | $457.3M | $339.7M | $554.1M | $454.6M |
| Capital expenditure | $17.8M | $20.6M | $20.8M | $30.6M | $43.0M | $28.5M | $33.7M | $51.1M |
| Free cash flow | $307.7M | $288.0M | $557.9M | $508.2M | $414.4M | $311.2M | $520.5M | $403.5M |
| Dividends paid | $77.9M | $77.7M | $77.7M | $77.6M | $87.8M | $87.6M | $87.2M | $87.1M |
| Share buybacks | $50.0M | $75.0M | $75.0M | $100.0M | $150.0M | $175.0M | $175.0M | $200.0M |
From ResMed's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About ResMed
Resmed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19. Resmed also provides software to out-of-hospital care agencies to streamline transitions of care into and between these care settings for seniors and their care providers.
- Headquarters
- San Diego, California From SEC filings, Oct 2026
Recent News (20)
-
ResMed chairman & CEO Michael Farrell sells $1.1m in shares
ResMed chairman & CEO Michael Farrell sells $1.1m in shares
-
Stifel reiterates Hold on ResMed stock amid market share concerns
Stifel reiterates Hold on ResMed stock amid market share concerns
-
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday,…
-
Her Husband Is Eleven Years Younger, and Because His Name Is the Only One on Her Beneficiary Form, the IRS Asks Her for a Smaller RMD Every Year Than Her Neighbor With the Same Balance
Her Husband Is Eleven Years Younger, and Because His Name Is the Only One on Her Beneficiary Form, the IRS Asks Her for a Smaller RMD Every Year Than Her Neighbor With the Same Balance
-
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
-
He Has Four IRAs and One RMD. Every December He Takes the Whole Thing From a Single Account and Never Touches the Other Three. The IRS Wrote the Rule Itself, and It Doesn’t Work for 401(k)s
He Has Four IRAs and One RMD. Every December He Takes the Whole Thing From a Single Account and Never Touches the Other Three. The IRS Wrote the Rule Itself, and It Doesn’t Work for 401(k)s
-
At 75 He Still Has a Paycheck and Still Hasn’t Taken a Single RMD From His 401(k). The Exception Is Written Into the Law, and the IRA Down the Street Doesn’t Get It
At 75 He Still Has a Paycheck and Still Hasn’t Taken a Single RMD From His 401(k). The Exception Is Written Into the Law, and the IRA Down the Street Doesn’t Get It
-
A $2.25 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does
A $2.25 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does
-
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
-
Retirees Who Turned 73 This Year Can Push Their First RMD to April 1. The Ones Who Do Take Two in 2027, and Some Pay a Medicare Bracket for It
Retirees Who Turned 73 This Year Can Push Their First RMD to April 1. The Ones Who Do Take Two in 2027, and Some Pay a Medicare Bracket for It
-
A 401(k) Millionaire’s First RMD Is About $37,700. Add a $40,000 Social Security Benefit and 85% of the Benefit Turns Taxable the Same Year
A 401(k) Millionaire’s First RMD Is About $37,700. Add a $40,000 Social Security Benefit and 85% of the Benefit Turns Taxable the Same Year
-
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
-
This Analyst Just Upgraded ResMed Stock. Here's Why.
This Analyst Just Upgraded ResMed Stock. Here's Why.
-
ResMed stock jumps 3% on RBC Capital upgrade to Outperform
ResMed stock jumps 3% on RBC Capital upgrade to Outperform
-
He Took Social Security at 62 to ‘Let the IRA Grow.’ It Grew Into a $24,000 RMD at 73, Taxed in the Bracket Social Security Had Already Filled
He Took Social Security at 62 to ‘Let the IRA Grow.’ It Grew Into a $24,000 RMD at 73, Taxed in the Bracket Social Security Had Already Filled
-
ResMed at Morgan Stanley healthcare conference: growth, margins, GLP-1 tailwind
ResMed at Morgan Stanley healthcare conference: growth, margins, GLP-1 tailwind
-
ResMed Stock: Is RMD Underperforming the Healthcare Sector?
ResMed Stock: Is RMD Underperforming the Healthcare Sector?
-
A 72-Year-Old Can Still Move Up to $210,000 Into a QLAC and Cut Next Year’s RMD by About $7,900. The Check Doesn’t Start Until 85, and Neither Does the Tax
A 72-Year-Old Can Still Move Up to $210,000 Into a QLAC and Cut Next Year’s RMD by About $7,900. The Check Doesn’t Start Until 85, and Neither Does the Tax
-
Why Retirees With $1.4 Million Are Taking $60,000 a Year at 62 Instead of Waiting for a $100,000 RMD at 73
Why Retirees With $1.4 Million Are Taking $60,000 a Year at 62 Instead of Waiting for a $100,000 RMD at 73
-
A $1.65 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does
A $1.65 Million Portfolio, Two Withdrawal Plans: One Triggers IRMAA and RMD Taxes, One Never Does
More Health Care stocks
- MTD Mettler Toledo
- PFE Pfizer
- PODD Insulet Corporation
- REGN Regeneron Pharmaceuticals
- RVTY Revvity
- SOLV Solventum
- STE Steris
- SYK Stryker Corporation